KRN633 (also known as KRN-633) is a small molecule inhibitor that has been developed to target the vascular endothelial growth factor receptor 2 (VEGFR-2) signaling pathway. This product has shown potential as a therapeutic agent for various types of cancer, including breast and lung cancer.
Chemical name: (Z)-N-(3-fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-2-(pyridin-2-yl)but-2-enamide
Molecular formula: C33H36FN5O4
Formula weight: 575.67 g/mol
CAS No: 286370-15-8
Top ten keywords from Google:
Health benefits of this product: The primary health benefit of KRN633 is its potential ability to inhibit the VEGFR-2 signaling pathway, which is involved in angiogenesis and tumor growth. By inhibiting VEGFR-2, KRN633 may prevent the formation of new blood vessels in tumors, thereby reducing their size and slowing their progression.
Potential effects: Due to its ability to inhibit VEGFR-2, KRN633 has shown promise as a therapeutic agent for various types of cancers, including breast and lung cancer. In preclinical studies, KRN633 has been shown to significantly reduce tumor growth and increase survival rates in animal models.
Product mechanism: KRN633 works by selectively inhibiting the activity of VEGFR-2, which is responsible for promoting the formation of new blood vessels in tumors. By inhibiting VEGFR-2, KRN633 can prevent the formation of new blood vessels, leading to reduced tumor growth and progression.
Safety: Although KRN633 has shown promising results in preclinical studies, its safety profile in humans is still being studied. In clinical trials, some adverse effects have been reported, including fatigue, nausea, and vomiting, among others. However, these side effects were generally mild and well-tolerated.
Side effects: As with any medication, there is a risk of side effects when taking KRN633. Some potential side effects include headache, fatigue, dizziness, nausea, vomiting, and diarrhea. If you experience any of these symptoms while taking KRN633, you should consult your healthcare provider immediately.
Dosing information: The optimal dosing regimen for KRN633 has not yet been established. However, current clinical trials are investigating doses ranging from 100mg to 500mg per day. Patients should follow their healthcare provider's instructions regarding dosing and administration.
Conclusion: KRN633 is a promising new VEGFR-2 inhibitor that has shown significant potential as an anti-tumor agent in preclinical studies. Although its safety and efficacy in humans are still being evaluated, early results suggest that it may be a valuable addition to the arsenal of cancer therapies. As further research is conducted, KRN633 may prove to be a valuable tool in the fight against cancer